Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open

Article Gastroenterology & Hepatology

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment

William J. Sandborn et al.

Summary: Tofacitinib demonstrated consistent safety over up to 7.0 years, with data up to Month 36 supporting long-term efficacy in the treatment of ulcerative colitis patients.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis

Parakkal Deepak et al.

Summary: In a real-world study of UC patients given tofacitinib, adverse events occurred in 15.7% of patients, most of which were infections. Serious adverse events occurred at a rate of 10.0%, with HZ infection and VTE primarily occurring in patients receiving 10 mg tofacitinib twice per day.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Kevin L. Winthrop et al.

Summary: The study reported the infection analysis of patients with ulcerative colitis treated with tofacitinib, revealing that serious infections were more frequent with tofacitinib compared to placebo during induction. In the maintenance and overall cohorts, infection rates were generally low and comparable between treatment groups, with viral infections being rare.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Rheumatology

Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation

Heike C. Hawerkamp et al.

Summary: In vitro, tofacitinib significantly reduces the gene expression of antiviral peptides in keratinocytes and synoviocytes, as well as decreasing T cell activation after stimulation with bacterial or viral proteins. This suggests that tofacitinib may impact antiviral immunity, leading to adverse events like herpes zoster in patients. However, antimicrobial immunity does not appear to be affected by JAK inhibition.

ARTHRITIS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Rheumatology

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis

Jon T. Giles et al.

Summary: This study investigated the impact of body mass index (BMI) on tofacitinib efficacy and safety in patients with PsA, and found that at month 3, tofacitinib demonstrated higher efficacy compared to placebo, but some efficacy measures were reduced in patients with baseline BMI >= 35.

RMD OPEN (2021)

添加到收藏夹

Review Medicine, General & Internal

Incidence and Prevalence of Inflammatory Bowel Disease across Asia

Jihye Park et al.

Summary: This review discusses the latest trends in the incidence and prevalence of inflammatory bowel diseases (IBD) in Asia, highlighting factors such as a Westernized diet, high socioeconomic status, improved hygiene, and vaccination development that may contribute to the increasing rates of IBD in Asian countries. Studying the epidemiology of IBD in Asia could help uncover the etiopathogenesis and risk factors of the disease.

YONSEI MEDICAL JOURNAL (2021)

添加到收藏夹

Article Dermatology